Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer

Yukio Hosomi, Masahiko Shibuya, Seiji Niho, Yukito Ichinose, Katsuyuki Kiura, Hiroshi Sakai, Koji Takeda, Shinzo Kudo, Kenji Eguchi, Kaoru Matsui, Noriyuki Masuda, Masahiro Ando, Koshiro Watanabe

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.

Original languageEnglish
Pages (from-to)3449-3456
Number of pages8
JournalAnticancer research
Volume31
Issue number10
Publication statusPublished - Oct 1 2011

Keywords

  • Cisplatin
  • Small cell lung cancer
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Hosomi, Y., Shibuya, M., Niho, S., Ichinose, Y., Kiura, K., Sakai, H., Takeda, K., Kudo, S., Eguchi, K., Matsui, K., Masuda, N., Ando, M., & Watanabe, K. (2011). Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer research, 31(10), 3449-3456.